| Species |
Human |
| Protein Construction |
Integrin alpha 8 beta 1 (ITGA8&ITGB1) Heterodimer [Phe39-Leu1012(ITGA8) acidic tail & Gln21-Asp728(ITGB1) basic tail]
Accession # P53708(ITGA8)&P05556-1(ITGB1) |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
113.90 kDa (ITGA8) & 83.2 kDa (ITGB1) |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 120-140 kDa (ITGA8) and 100-120 kDa (ITGB1) based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Human Integrin alpha 8 beta 1 is a heterodimeric glycoprotein composed of integrin alpha 8 and integrin beta 1 that mainly expressed in smooth muscle cells. It functions as a receptor for Tenascin, Fibronectin, and Vitronectin and can promote attachment, cell spreading, and neurite outgrowth. |
| Synonyms |
ITGA8&ITGB1; ; α8β1; Integrin alpha 8 beta 1; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
